Stock Code: 300238 Stock Abbreviation: Guanhao Biotech
Guanhao Biotech Co., Ltd. (No. 12 Yuyan Road, Huangpu District, Guangzhou, Guangdong Province)
Issuer Statement
-
The Company and all members of the Board of Directors guarantee that the contents of this plan are true, accurate, and complete, and confirm that there are no false records, misleading statements, or major omissions.
-
This plan is prepared in accordance with the Company Law of the People's Republic of China, the Securities Law of the People's Republic of China, the Administrative Measures for the Issuance and Registration of Securities by Listed Companies, and other laws, regulations, and normative documents.
-
After the completion of this issuance of shares to specific targets via the simplified procedure, the Company is solely responsible for changes in its operations and earnings; investors are solely responsible for investment risks arising from this issuance.
-
This plan is the Board of Directors' explanation of this issuance of shares to specific targets via the simplified procedure; any statement to the contrary is a false statement.
-
If investors have any questions, they should consult their stockbroker, lawyer, professional accountant, or other professional advisor.
-
The matters described in this plan do not represent a substantive judgment, confirmation, approval, or registration by the approval authorities regarding the matters related to this issuance. The effectiveness and completion of this issuance are subject to the approval or registration of the relevant approval authorities.
Important Notice
The terms or abbreviations used in this section have the same meanings as those defined in the "Definitions" section of this plan.
-
The matters related to this issuance of shares to specific targets via the simplified procedure have been authorized by the Company's 2025 Annual General Meeting to the Board of Directors for implementation. The issuance plan and related matters have been reviewed and approved at the 19th meeting of the 6th Board of Directors and the 2nd meeting of the 7th Board of Directors. It is still subject to approval by the Shenzhen Stock Exchange and registration by the China Securities Regulatory Commission before it can be implemented. The final issuance plan shall be subject to the plan approved by the China Securities Regulatory Commission.
-
The targets of this issuance are Yuecai (Zhongshan) Biomedical Investment Partnership (Limited Partnership), Nord Fund Management Co., Ltd., Caitong Fund Management Co., Ltd., and Yang Yin. All targets of this issuance subscribe to the shares at the same price and in cash.
-
Based on the bidding results, the total amount of funds intended to be raised is 97,499,995.74 RMB, which does not exceed 300 million RMB and does not exceed 20% of the net assets at the end of the most recent year. After deducting relevant issuance expenses, the net proceeds will be used for the following projects:
| No. | Project Name | Total Investment | Proposed Investment Amount |
|---|---|---|---|
| 1 | Biological Dural Repair Material (3rd Gen) Industrialization Project | 7,363.12 | 6,825.00 |
| 2 | Supplementing Working Capital and Repaying Bank Loans | 2,925.00 | 2,925.00 |
| Total | 10,288.12 | 9,750.00 |
Unit: 10,000 RMB
Before the raised funds are in place, the Company will invest with its own or self-raised funds according to the actual progress of the projects and will replace them according to procedures stipulated by relevant laws and regulations after the funds are in place. If the actual net proceeds after deducting issuance expenses are less than the proposed investment amount, the Company will adjust the investment sequence and amount for the above projects within the scope of the investment projects based on the actual amount of funds raised. Any shortfall will be covered by the Company's own or self-raised funds.